Oral Session 3-13A MPN: Clinical (Variants)

[OS3-13A-6] A case that developed CML and DLBCL during ruxolitinib therapy for patient with MF post ET

Takeshi Okatani¹, Yuta Katayama¹, Tatsuya Terasaki¹, Takuya Nunomura¹, Fumiaki Jinnouchi¹, Ryota Imanaka¹, Kohei Kyo¹, Mitsuhiro Itagaki¹, Shinya Katsutani¹, Tsuyoshi Muta², Koji Iwato³, Megumu Fujiwara⁴, Hideki Asaoku¹, Taiichi Kyo⁵ (1.Hematol., Hiroshima Red Cross Hosp. & Atomic-bomb Survivors Hosp., Japan, 2.Transfusion, Hiroshima Red Cross Hosp. & Atomic-bomb Survivors Hosp., Japan, 3.Labo., Hiroshima Red Cross Hosp. & Atomic-bomb Survivors Hosp., Japan, 4.Pathol., Hiroshima Red Cross Hosp. & Atomic-bomb Survivors Hosp., Japan, 5.Hematol., Itsukaichi Memorial Hosp., Japan)